ServiceNow Inc vs ResMed Inc. — how do they compare? ServiceNow Inc trades at $101.36 (market cap $107.98B), while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: ServiceNow Inc is far larger — about 3.7× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.21% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| NOW | RMD | |
|---|---|---|
Market Cap | $107.98B | $28.81B |
Sector | Technology | Health |
52-Week High | $199.24 | $293.73 |
52-Week Low | $83.00 | $182.82 |
Enterprise Value | $105.23B | $27.99B |
Dividend Yield | — | 1.21% |
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $103.24, down 0.74% today, with a bearish technical signal but strong fundamentals including 76.56% gross margins and consistent revenue growth to $13.28B in 2025. The stock shows robust cash flow generation of $5.44B from operations and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth opportunities and conference presentations.
Outlook remains positive with an 85.51% analyst buy rating and $135.14 consensus price target, suggesting 31% upside. Key risks include high valuation multiples (P/E 62.32) and competitive pressures in enterprise software. Earnings execution and AI adoption present the primary catalysts for continued appreciation.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →